RPTX (Repare Therapeutics) ROE % Adjusted to Book Value: 17.52% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPTX Repare Therapeutics Inc RPTX
20 GF Score
Price $2.65
GF Value $0.94
! 6 Warning Signs
View Full Analysis

What is Repare Therapeutics ROE % Adjusted to Book Value?

Repare Therapeutics RPTX 20 ROE % Adjusted to Book Value is 17.52% as of Sep. 2025. GuruFocus rates RPTX with a GF Score™ of 20/100 and a GF Value™ of $0.94. The stock has 6 warning signs investors should review.

Repare Therapeutics's ROE % for the quarter that ended in Sep. 2025 was 11.56%. Repare Therapeutics's PB Ratio for the quarter that ended in Sep. 2025 was 0.66. Repare Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 was 17.52%.

Repare Therapeutics ROE % Adjusted to Book Value Related Terms

Repare Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Repare Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repare Therapeutics ROE % Adjusted to Book Value Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -10.06 -12.15 -4.63 -26.32 -126.03

Repare Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.54 -190.11 -255.91 -105.33 17.52

RPTX vs MGNX, THAR, ANIX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Repare Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repare Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's ROE % Adjusted to Book Value falls into.


RPTX
20GF Score
Repare Therapeutics Inc RPTX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repare Therapeutics ROE % Adjusted to Book Value Calculation

Repare Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-46.63% / 0.37
=-126.03%

Repare Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=11.56% / 0.66
=17.52%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 17.52% mean?
Repare Therapeutics (RPTX) has a ROE % Adjusted to Book Value of 17.52% as of Sep. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Repare Therapeutics and its competitors.
Is Repare Therapeutics' ROE % Adjusted to Book Value too high?
Repare Therapeutics' current ROE % Adjusted to Book Value is 17.52%. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' ROE % Adjusted to Book Value compare to MGNX and THAR?
Repare Therapeutics' ROE % Adjusted to Book Value of 17.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Repare Therapeutics and its competitors. Repare Therapeutics's current ROE % Adjusted to Book Value is 17.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current ROE % Adjusted to Book Value of 17.52%. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current ROE % Adjusted to Book Value is 17.52%. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current ROE % Adjusted to Book Value is 17.52% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repare Therapeutics (RPTX) Overvalued in 2026?

Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued. The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.

Key valuation signals for RPTX:

  • ROE % Adjusted to Book Value: 17.52%
  • GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
  • GF Score™: 20/100 with 6 warning signs

No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repare Therapeutics Business Description

Address 7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score

Get the complete analysis for RPTX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.65
Price
$0.94
GF Value